CJC-1295 WITH DAC (Drug Affinity Complex): Standard protocol: Total weekly: 2mg Split into: 1mg twice weekly (Monday/Thursday) OR: Single 2mg injection weekly Duration: 12-16 weeks Conservative protocol: Total weekly: 1mg Single injection weekly Good for first-timers Still effective, lower cost Aggressive protocol: Total weekly: 3-4mg Split into 1.5-2mg twice weekly Used by advanced users Diminishing returns above 2mg for most Why DAC version: Long half-life (6-8 days) Sustained GH elevation Weekly or twice-weekly injections (convenient) Most popular version CJC-1295 WITHOUT DAC (Mod GRF 1-29): Standard protocol: Dose: 100mcg per injection Frequency: 2-3x daily Timing: With Ipamorelin doses Total weekly: 1.4-2.1mg (200-300mcg daily) Typical schedule: Morning: 100mcg CJC + 200mcg Ipamorelin Post-workout: 100mcg CJC + 200mcg Ipamorelin Before bed: 100mcg CJC + 200mcg Ipamorelin Why without DAC: Mimics natural GH pulses Doesn't desensitize pituitary More "natural" approach More frequent injections (downside) Which to choose: Choose WITH DAC if: Want convenience Don't want daily injections Okay with steady GH elevation Most people choose this Choose WITHOUT DAC if: Want natural pulsing GH Already injecting daily (stacking) Prefer physiological approach Don't mind multiple daily injections FREE TOOLS FAQ What does "stacking" peptides mean

But going lower would have taken me to college/high school era weight
It is often recommended to be taken on an empty stomach to aid absorption and metabolism
Here are some medications that providers often prescribe: Tirzepatide (Mounjaro/Zepbound) Semaglutide (Wegovy/Ozempic/Rybelsus) Liraglutide (Saxenda/Victoza) Topiramate (Topamax/Qudexy XR/Trokendi XR) Bupropion (Zyban/Contrave/Aplenzin) Naltrexone (Vivitrol/Apo-Naltrexone/ReVia/Contrave) Orlistat (Xenical/Alli) What is Wegovy
Best BPC-157 Peptides 2026: 10 Top Brands Tested & Ranked We independently tested 10 BPC-157 supplements for purity, bioavailability, and value
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes